FIGO Cancer Report 2021: diagnosis and management of gestational trophoblastic disease
The FIGO review of trophoblastic disease from molar pregnancy to choriocarcinoma and the rare placental-site and epithelioid tumours: hCG surveillance, the risk score, single-agent or EMA/CO chemotherapy, surgery, and immunotherapy for resistant disease.
Overview
FIGO Cancer Report chapter covering hydatidiform mole and its follow-up, the FIGO 2000 staging and scoring of gestational trophoblastic neoplasia, single-agent therapy for low-risk and EMA/CO for high-risk disease, induction etoposide-cisplatin for ultra-high-risk disease, salvage regimens, the role of hysterectomy and metastasectomy, management of placental-site and epithelioid trophoblastic tumours, immunotherapy for resistant disease, and follow-up and future pregnancy.
The standard-of-care rows on all three trophoblastic pages follow this report and the national centres it describes.
- Evidence in this rare disease is mostly from specialist centre series rather than randomised trials.
- Updated periodically; check the current FIGO report.
Similar pages
not linked directly; found by shared links- Key paperEMA/CO for high-risk gestational trophoblastic tumours: results from a cohort of 272 patients
Shares Dactinomycin (actinomycin D), High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk), Methotrexate, Etoposide.
- Key paperPrognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study
Shares Placental-site trophoblastic tumour and epithelioid trophoblastic tumour, Etoposide, Cisplatin.
- Key paperIntensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours
Shares Placental-site trophoblastic tumour and epithelioid trophoblastic tumour, Etoposide, Cisplatin.
- CancerGestational trophoblastic neoplasia
Shares Placental-site trophoblastic tumour and epithelioid trophoblastic tumour, Dactinomycin (actinomycin D), High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk), Methotrexate.
- Key paperGOG 174: weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia
Shares Dactinomycin (actinomycin D), Methotrexate.
- CancerLow-risk gestational trophoblastic neoplasia (FIGO score 0 to 6)
Shares Placental-site trophoblastic tumour and epithelioid trophoblastic tumour, Dactinomycin (actinomycin D), High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk), Methotrexate.
- TrialPembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
Shares Etoposide, Cisplatin, Pembrolizumab.
- TrialStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
Shares Etoposide, Cisplatin, Pembrolizumab.